Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that would allow a substantial number of patients with prostate cancer to benefit from immunotherapies.
Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms. In a paper published in the leading cancer journal Annals of Oncology, researchers report that the test accurately detected cancer, often before any symptoms arose, while having a very low false positive rate.
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer. Approved by the FDA last month, the radiotracer identified metastatic lesions with high positive predictive values regardless of anatomic region, adding to the evidence that PSMA-targeted radiotracers are the most sensitive and accurate agents for imaging prostate cancer. This study was presented at the SNMMI 2021 Annual Meeting.
Abdominal obesity appears to be associated with a greater risk of developing aggressive prostate cancer. This link was demonstrated in a study led by Professor Marie-Élise Parent of Institut national de la recherche scientifique (INRS) and published in the journal Cancer Causes & Control.
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
'Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months.'
A new, retrospective study focuses on men who have both high-grade prostate cancer that extends outside the prostate and/or has spread into the lymph nodes. For these men who are at high risk of dying from the disease, there was a significant reduction in the risk of death with adjuvant radiation therapy (aRT) use, suggesting that it should be offered to these men.
A new kind of prostate cancer treatment tested at Oregon Health & Science University combines a targeting compound with a radioactive isotope to irradiate and kill cancer cells, sparing most normal tissues.
"Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually."